PRECIGEN, INC.
Close on Oct 19, 2026
- Market cap
- $2.76B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 12, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | During market hours | $55.00M | $0.05 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | During market hours | $23.25M | $-0.02 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 25, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | During market hours | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 19, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | $953.00K | $-0.09 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | During market hours | $717.00K | $-0.23 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | During market hours | $1.07M | $-0.10 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 19, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 9, 2023 | During market hours | $1.38M | $-0.08 | – |
Press releases
Announcements Precigen filed with the SEC
Precigen Reports Second Quarter 2026 Financial
Results of operations · EX-99.1 to Form 8-K
Precigen Reports First Quarter 2026 Financial Results and Business
Results of operations · EX-99.1 to Form 8-K
Precigen Reports Full Year 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Precigen Reports Third Quarter 2025 Financial
Results of operations · EX-99.1 to Form 8-K
Precigen Announces Up to $125 Million Non-Dilutive Financing
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
“project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are
Regulation FD disclosure · EX-99.1 to Form 8-K
Precigen Reports First Quarter 2025 Financial Results and Business
Results of operations · EX-99.1 to Form 8-K
Precigen Reports Full Year 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Private Placement Offering of Convertible Preferred Stock
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory
Material agreement · Unregistered share sale · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Precigen Reports Third Quarter 2024 Financial
Results of operations · EX-99.1 to Form 8-K
Precigen Reports Second Quarter and First Half
Results of operations · EX-99.1 to Form 8-K
Prioritizes Portfolio to Focus on First Potential
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Precigen Announces Proposed $30 Million Public
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Precigen Reports First Quarter 2024 Financial
Results of operations · EX-99.1 to Form 8-K
Precigen Reports Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Precigen Highlights Pipeline Updates to be Presented
Regulation FD disclosure · EX-99.1 to Form 8-K
Precigen Reports Third Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Precigen Reports Second Quarter and First Half
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Precigen Announces FDA Confirmation that the
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Precigen Reports First Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Precigen Reports Fourth Quarter and Full Year
Results of operations · EX-99.1 to Form 8-K
Precigen Announces Positive Phase 1 Dose Escalation
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Precigen Provides Pipeline and Corporate Updates
Regulation FD disclosure · EX-99.1 to Form 8-K
Precigen Reports Third Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Precigen Completes Sale of Non-Healthcare Subsidiary
Acquisition or disposition completed · Other events · EX-99.1 to Form 8-K
Precigen Reports Second Quarter and First Half
Results of operations · EX-99.1 to Form 8-K
into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics
Material agreement · Other events · EX-99.1 to Form 8-K
Precigen Reports First Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Precigen Reports Fourth Quarter and Full Year
Results of operations · EX-99.1 to Form 8-K
Precigen Achieves Significant Clinical Progress
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K